Table S1.
Analysis of risk factors for mortality in patients with BSI caused by CnSKP
| Univariate analysis
|
Multivariable analysis
|
||||||
|---|---|---|---|---|---|---|---|
| Survivors (55) | Nonsurvivors (52) | P-values | Sig. | Exp(B) | 95% CI for Exp(B)
|
||
| Lower | Upper | ||||||
| Demographic | |||||||
| Gender, male, n (%)q | 42 (76.4) | 39 (75) | 0.869 | ||||
| Age, years, mean ± SD | 57.8±16.5 | 59.1±15.2 | 0.679 | ||||
| Duration before bacteremia, days (IQR) | 19 (6–32) | 18 (7–49.5) | 0.781 | ||||
| Comorbid conditions | |||||||
| CCI score (≥3), n (%) | 25 (45.5) | 24 (46.2) | 0.942 | ||||
| Respiratory failure | 1 (1.8) | 8 (15.4) | 0.014 | ||||
| Heart failure | 1 (1.8) | 5 (9.6) | 0.106 | ||||
| Kidney failure | 3 (5.5) | 4 (7.7) | 0.711 | ||||
| Multiple organ failure | 5 (9.1) | 20 (38.5) | <0.001 | 0.004 | 5.498 | 1.727 | 17.504 |
| Prior ICU staya | 35 (63.6) | 37 (71.2) | 0.407 | ||||
| Invasive procedure or devicesa | 30 (54.5) | 33 (63.5) | 0.349 | ||||
| Mechanical ventilation | 38 (69.1) | 45 (86.5) | 0.031 | ||||
| Central venous catheterization | 36 (65.5) | 45 (86.5) | 0.011 | 0.013 | 3.704 | 1.325 | 10.356 |
| Urinary catheterization | 42 (76.4) | 47 (90.4) | 0.053 | ||||
| Invasive procedure or devices after BSI | 18 (32.7) | 9 (17.3) | 0.066 | ||||
| Mechanical ventilation | 25 (45.5) | 42 (80.8) | <0.001 | ||||
| Central venous catheterization | 29 (52.7) | 44 (84.6) | <0.001 | ||||
| Urinary catheterization | 36 (65.5) | 47 (90.4) | 0.002 | ||||
| Prior receipt of antibiotics within 14 days before BSI | b | ||||||
| Number of antibiotics | 2 (1–3) | 2 (2–3) | 0.157 | ||||
| Severity of illness at the time of BSI | |||||||
| Mean APACHE II score ± SD | 11.55±5.266 | 15.62±5.15 | <0.001 | 0.002 | 1.154 | 1.054 | 1.263 |
| Total antimicrobial regimen after BSI | |||||||
| Tigecycline | 30 (54.5) | 34 (65.4) | 0.253 | ||||
| <0.2 g/day | 14 (25.5) | 17 (32.7) | 0.790 | ||||
| ≥0.2 g/day | 16 (29.1) | 17 (32.7) | |||||
| Carbapenem | 37 (67.3) | 34 (65.4) | 0.836 | ||||
| MIC <4 μg/mL | 6 (16.2) | 1 (2.9) | 0.109 | ||||
| MIC ≥8 μg/mL | 31 (83.8) | 31 (91.2) | 0.482 | ||||
| Aminoglycoside | 11 (20) | 13 (25) | 0.535 | ||||
| Fluoroquinolone | 9 (16.4) | 10 (19.2) | 0.698 | ||||
| Appropriate empirical treatment | 9 (16.4) | 9 (17.3) | 0.896 | ||||
| 1) Monotherapy | 24 (43.6) | 14 (26.9) | 0.071 | ||||
| 2) Combination therapy | 31 (56.4) | 38 (73.1) | |||||
| Appropriate definitive treatment | 20 (36.4) | 25 (48.1) | 0.220 | ||||
| 1) No active drug | 34 (61.8) | 27 (51.9) | 0.236 | ||||
| 2) At least two active drugs | 3 (5.5) | 6 (11.5) | |||||
| 3) One active drug | 18 (32.7) | 19 (36.5) | |||||
| Antimicrobial regimen | |||||||
| 1) Tigecycline monotherapy | 6 (10.9) | 2 (3.8) | 0.272 | ||||
| 2) Tigecycline combination therapy | 24 (43.6) | 32 (61.5) | 0.064 | ||||
| APACHE II <15 | 16 (66.7) | 16 (50) | 0.212 | ||||
| APACHE II ≥15 | 8 (33.3) | 16 (50) | |||||
| 3) Carbapenem monotherapy | 11 (20) | 6 (11.5) | 0.231 | ||||
| 4) Carbapenem-containing regimen | 26 (47.3) | 28 (53.8) | 0.497 | ||||
| MIC <4 μg/mL | 3 (11.5) | 1 (3.6) | 0.342 | ||||
| MIC ≥8 μg/mL | 23 (88.5) | 25 (89.3) | 1.000 | ||||
Notes: Data are expressed as number (%) unless otherwise stated;
a
During the 30 days preceding BSI onset
b
during the 14 days preceding BSI onset.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BSI, bloodstream infection; CCI, Charlson comorbidity index; CI, confidence interval; CnSKP, carbapenem-nonsusceptible KP; CSKP, carbapenem-susceptible KP; ICU, intensive care unit; KP, Klebsiella pneumoniae; IQR, interquartile range; MIC, minimum inhibitory concentration; SD, standard deviation.